HealthPolitics

Opinion: How CMS plans to fix a major flaw in the 340B drug discount program

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 08/10/2026, 22:36:26 UTC.

Briefings

The Department of Health and Human Services proposes narrowing the gap between hospital costs and Medicare reimbursement for 340B drugs, a gap caused by the 1992 Congressional mandate requiring manufacturers to discount prices. This initiative aims to reduce the financial spread that allows hospitals to retain funds from high-cost drugs. The proposal addresses a systemic issue where Medicare patients often owe more in coinsurance than the hospital paid, a consequence of the current payment formula.

Key points

• The 340B drug discount program was established in 1992 by Congress to financially support safety net hospitals serving low-income patients.
• Medicare reimbursement for these drugs is currently set at the full amount, whereas manufacturers provide steep discounts, creating a financial spread that hospitals must cover.

Context

This finding addresses a critical issue in US healthcare where hospitals serving low-income patients face significant financial risks due to the 340B program's payment formula.

Limitations

Evidence is limited to the Department of Health and Human Services proposal; specific implementation details, timeline, or outcomes are not provided.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 25/10/2026, 01:51:59 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeields4lsebh35lgaow2sijeqtef2xreb2ibpvv5i5oiluqxvw2rxq